65563-75-9Relevant articles and documents
Sesquiterpene lactone nitrogen methyl piperazine derivative and salt thereof, and application thereof in medicine preparation
-
Paragraph 0032-0033, (2021/05/01)
The invention relates to sesquiterpene lactone nitrogen methyl piperazine derivatives and pharmaceutically acceptable salts thereof, and applications thereof in medicine preparation. The invention concretely relates to compounds represented by formulas (I), (II), (III) and (IV), and pharmaceutically acceptable salts thereof, as well as the applications of the compounds shown in formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts and compositions thereof for preparing anti-cancer or auxiliary anti-cancer drugs.
Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway
Li, Xiaohe,Lu, Cheng,Liu, Shuangwei,shuaishuai Liu,Su, Chengcheng,Xiao, Ting,Bi, Zhun,Sheng, Pengzhen,Huang, Mengying,Liu, Xinhua,Wei, Yujiao,Zhao, Lin,Miao, Shengxiang,Mao, Jiahe,Huang, Kai,Gao, Shaoyan,Liu, Ning,Qi, Min,Liu, Tongtong,Qin, Shuanglin,Wei, Luqing,Sun, Tao,Ning, Wen,Yang, Guang,Zhou, Honggang,Yang, Cheng
, p. 229 - 247 (2018/08/10)
In this study, anti-IPF lead compounds 42 and 44, derived from natural sesquiterpene lactones Isoalantolactone and alantolactone, were discovered by screening from a high-throughput TGF-β1 reporter luciferase assay. Notably, they could reduce the myofibroblast activation and extracellular matrix deposition both in vitro and in vivo. Additionally, compounds 42 and 44 could significantly attenuate bleomycin-induced pulmonary fibrosis in mice. Further validation of pharmacokinetics study and toxicity evaluation indicated that compound 44 might be a promising anti-IPF drug candidate.
Application of alantolactone derivative and salt thereof in preparing drug for treating thyroiditis
-
Paragraph 0028; 0031; 0032; 0033, (2017/08/28)
The invention relates to application of an alantolactone derivative and salt thereof in preparing a drug for treating thyroiditis, and provides application of the alantolactone derivative as the formula (I-II) or the formula (I-III) and the salt thereof in preparing the drug for treating thyroiditis. Acid for forming the salt is inorganic or organic acid, the inorganic acid is selected from hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, boracic acid, seleninic acid, phosphomolybdic acid, phosphorous acid and sulphurous acid, and the organic acid is selected from citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, methanesulfonic acid, pentanoic acid, oleic acid, lauric acid, p-methylbenzene sulfonic acid, 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, glycollic acid, mercaptan acid, glycine, sarcosine, sulfonic acid, nicotinic acid, methylpyridine, isonicotinic acid, benzoic acid and substituted benzoic acid.